Kymera Therapeutics’ (KYMR) “Buy” Rating Reiterated at BTIG Research

Kymera Therapeutics (NASDAQ:KYMR)‘s stock had its “buy” rating reissued by investment analysts at BTIG Research in a report released on Thursday,Benzinga reports. They presently have a $138.00 price target on the stock. BTIG Research’s price target suggests a potential upside of 83.49% from the stock’s current price.

Other equities research analysts also recently issued research reports about the stock. UBS Group raised shares of Kymera Therapeutics to a “strong-buy” rating in a research report on Thursday, December 4th. Leerink Partners lifted their price target on Kymera Therapeutics from $70.00 to $118.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Royal Bank Of Canada upped their price objective on Kymera Therapeutics from $70.00 to $103.00 and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Guggenheim began coverage on Kymera Therapeutics in a research note on Monday, November 3rd. They set a “buy” rating and a $90.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Buy” and an average target price of $116.30.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $75.21 on Thursday. Kymera Therapeutics has a one year low of $19.44 and a one year high of $103.00. The stock has a 50-day moving average price of $73.78 and a 200 day moving average price of $57.60. The company has a market capitalization of $5.41 billion, a P/E ratio of -20.95 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. The business had revenue of $2.76 million during the quarter, compared to analyst estimates of $23.15 million. As a group, equities research analysts forecast that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Insider Activity at Kymera Therapeutics

In other news, Director Bros. Advisors Lp Baker bought 2,005,813 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was purchased at an average price of $86.00 per share, for a total transaction of $172,499,918.00. Following the transaction, the director owned 7,955,916 shares in the company, valued at approximately $684,208,776. This trade represents a 33.71% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Jared Gollob sold 49,307 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $88.67, for a total value of $4,372,051.69. Following the transaction, the insider owned 109,992 shares of the company’s stock, valued at approximately $9,752,990.64. This represents a 30.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 450,895 shares of company stock valued at $39,608,051. Company insiders own 16.01% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. BVF Inc. IL boosted its position in Kymera Therapeutics by 6.6% during the 2nd quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock worth $240,138,000 after acquiring an additional 340,909 shares during the period. Geode Capital Management LLC lifted its holdings in Kymera Therapeutics by 5.2% in the second quarter. Geode Capital Management LLC now owns 1,193,112 shares of the company’s stock worth $52,075,000 after purchasing an additional 59,347 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Kymera Therapeutics by 121.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after buying an additional 491,737 shares in the last quarter. Holocene Advisors LP bought a new position in Kymera Therapeutics in the 3rd quarter valued at about $47,563,000. Finally, Jennison Associates LLC increased its stake in Kymera Therapeutics by 49.4% during the 2nd quarter. Jennison Associates LLC now owns 825,025 shares of the company’s stock valued at $36,004,000 after buying an additional 272,739 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.